TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03388788
Drug: 11C-Meta-Hydroxyephedrine (mHED)
Normalized name: 4-hydroxyephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 11C-meta-hydroxyephedrine will be used during PET imaging to measure cardiac presynaptic norepinephrine transporter function.
Study: NCT03388788
Drug: 11C-CGP12177
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac beta adrenergic receptor density will be measured via PET imaging with infusion of 11C-CGP12177.
Study: NCT03388788
Drug: O15-water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood flow will be measured via PET imaging with infusion of O15-water.
Study: NCT01880567
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00155246
Drug: pentoxifylline (drug)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04043676
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patient will take 15 mg/day ponatinib oral during 48 weeks.
Study: NCT00702949
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT03687957
Drug: rhIL-7-hyFc
Normalized name: rhIL-7-hyFc
DrugBank: Efineptakin alfa (DB16395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Given by intramuscular injection
Study: NCT03687957
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -Standard of care
Study: NCT03974854
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy with Gemcitabine regimen
Study: NCT01469637
Drug: sulfamethoxazole + MMX placebo
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.
Study: NCT01469637
Drug: Sulfamethoxazole + MMX Mesalazine/mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
Study: NCT02690506
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00400478
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)
Study: NCT01200758
Drug: Rituximab SC
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
Study: NCT01200758
Drug: Rituximab IV
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.
Study: NCT01200758
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight cycles of doxorubicin (1.4 mg/m\^2 IV) administered every 3 weeks.
Study: NCT00609791
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/m2 3 weeks on 1 week off
Study: NCT01200758
Drug: Prednisone/Prednisolone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m\^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
Study: NCT04460651
Drug: Icosapent ethyl (IPE)
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants in this arm will receive study medication IPE with the following dosage schedule:~8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
Study: NCT00790803
Drug: Pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Five patients will receive intravitreous injections of Macugen 0.3 mg every 6 weeks as needed for a total of no more than five.
Study: NCT04205240
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04205240
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04205240
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT04205240
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or IV
Study: NCT01383928
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib capsules
Study: NCT01383928
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide capsules
Study: NCT03033290
Drug: Bu-Zhong-Yi-Qi-Tang
Normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi-tonifying regimen of traditional Chinese herbal medicine
Study: NCT01383928
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone Tablets
Study: NCT02798159
Drug: Sildenafil Citrate 50mg
Normalized name: SILDENAFIL CITRATE 50MG TAB
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03525613
Drug: APL-2
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complement (C3) Inhibitor
Study: NCT03359538
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
Study: NCT00004688
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004688
Drug: streptozocin
Normalized name: Streptozocin
DrugBank: Streptozocin (DB00428)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00580619
Drug: L-NMMA trimethaphan
Normalized name: trimethaphan
DrugBank: Trimethaphan (DB01116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each
Study: NCT00580619
Drug: methyldopa
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aldomet oral twice a day for 12 weeks
Study: NCT03480360
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 daily for 5 days
Study: NCT03480360
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.
Study: NCT03480360
Drug: cellcept
Normalized name: Cellcept
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.
Study: NCT03480360
Drug: g-csf
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) \> 1000/mcL for 3 days.
Study: NCT04163562
Drug: INP20
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part A: Oral INP20 administration at ascending doses once daily for 2 weeks. Part B: Two doses of oral INP20 derived from Part A once daily for 6 months.
Study: NCT02528461
Drug: Galactose
Normalized name: Galactose
DrugBank: Galactose (DB11735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.
Study: NCT02528461
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02365961
Drug: clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04131504
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No standard dosing regimen will be used and the dose will be determined by the treating physician
Study: NCT04131504
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No standard dosing regimen will be used and the dose will be determined by the treating physician
Study: NCT00004795
Drug: dehydroepiandrosterone
Normalized name: Dehydroepiandrosterone
DrugBank: Prasterone (DB01708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00461552
Drug: Leptin
Normalized name: Leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: weight based, sub-cutaneous injection, twice daily
Study: NCT00660816
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally once daily on days 2-19.
Study: NCT00660816
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV over 10 minutes on day 1
Study: NCT00660816
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV over 60 minutes on day 1.
Study: NCT01756482
Drug: GS-5806
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-5806, powder for oral solution
Study: NCT00283062
Drug: Docetaxel (TAXOTERE®) Chemotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy.
Study: NCT00283062
Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
Study: NCT00283062
Drug: Docetaxel (TAXOTERE®) Chemotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy.
Study: NCT00283062
Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
Study: NCT00283062
Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
Study: NCT03054519
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be prescribed up to 2,000 mgs daily of metformin
Study: NCT01766609
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00066716
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosed to an AUC of 6 by the Calvert formula, intravenously over 1 hour after paclitaxel on days 1, 22, and 43.
Study: NCT00066716
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg/m2 as a 3-hour intravenous infusion on days 1, 22, and 43.
Study: NCT04619680
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg PO twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
Study: NCT02879162
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02879162
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03541083
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: prephase and consolidation (I and II)
Study: NCT04631510
Drug: Gabapentin 300 mg PO at 8 PM
Normalized name: gabapentin 300 MG
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer gabapentin 300 mg PO at 8 PM for sleep
Study: NCT02824029
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03113851
Drug: rhGM-CSF
Normalized name: rhGm-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy
Study: NCT02325934
Drug: Stribild
Normalized name: Stribild
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil
Study: NCT00409643
Drug: valsartan+amlodipine combination
Normalized name: amlodipine / valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02518594
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg micronized vaginal progesterone softgel capsule, daily from randomization to \< 35 wks
Study: NCT00409643
Drug: valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00409643
Drug: amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04531176
Drug: Phentermine / Topiramate Extended Release Oral Capsule
Normalized name: phentermine / topiramate Extended Release Oral Capsule
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication for chronic weight management (Rx)
Study: NCT04531176
Drug: naltrexone/bupropion extended-release
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication for chronic weight management (Rx)
Study: NCT04531176
Drug: liraglutide 3.0 mg
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Medication for chronic weight management (Rx)
Study: NCT04531176
Drug: Orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication for chronic weight management (Rx)
Study: NCT02244541
Drug: ANAVEX2-73 Oral
Normalized name: ANAVEX2-73
DrugBank: Blarcamesine (DB05592)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02244541
Drug: ANAVEX2-73 Intravenous
Normalized name: ANAVEX2-73
DrugBank: Blarcamesine (DB05592)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02244541
Drug: ANAVEX2-73 Oral
Normalized name: ANAVEX2-73
DrugBank: Blarcamesine (DB05592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg hard gelatin capsule
Study: NCT02244541
Drug: ANAVEX2-73 Oral
Normalized name: ANAVEX2-73
DrugBank: Blarcamesine (DB05592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hard gelatin capsule
Study: NCT04304820
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Between 12 and 17yo (adult dose of 150mg) Between 6 and 11yo (75 mg) Between 3 and 5 yo (2.5 mg/kg)
Study: NCT04304820
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 to start of h-ATG: 2mg/kg/day by mouth (All subjects) Start of h-ATG to Month 6: 3 mg/kg/dose by mouth administered every 12 hours (12yo and above) 6 mg/kg/dose by mouth administered every 12 hours (less than 12yo) Month 6 to Month 24: Dosing to be adjusted based on response
Study: NCT04304820
Drug: Horse-Anti-thymocyte-Globulin
Normalized name: Horse anti-thymocyte globulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: h-ATG at a dose of 40 mg/kg/day for 4 days (intravenously for approximately 4 hours daily) Note: Omitted in patients who have achieved a complete response at the initial NIH visit after initiating oral treatment remotely
Study: NCT01003301
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
Study: NCT03975010
Drug: Buprenorphine Transdermal Patch
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7\~9 days after patch removal.~The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal.
Study: NCT04240210
Drug: Symtuza
Normalized name: Symtuza
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The study is a prospective cohort analysis of change in adherence, tolerability and safety of subjects who reports poor adherence to ART due to intolerance/side effects from integrase inhibitor containing regimens when they are switched to DRV/COB/FTC/TAF and monitored for 4 months.
Study: NCT00181896
Drug: bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label prescription of Bupropion SR for 8 weeks.
Study: NCT04662385
Drug: aloe vera toothpaste
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aloe vera toothpaste have antimicrobial and other multipotential effects.
Study: NCT02516696
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
Study: NCT02516696
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
Study: NCT00039104
Drug: rebimastat
Normalized name: Rebimastat
DrugBank: Rebimastat (DB06573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04094597
Drug: Lactoferrin
Normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactoferrin is given orally in comparsion to placebp
Study: NCT01451606
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week
Study: NCT02718898
Drug: Ixekizumab
Normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT01161940
Drug: Nizatidine
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
Study: NCT01161940
Drug: Axid
Normalized name: Axid
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axid 300 mg Capsules of Reliant Pharmaceuticals, US
Study: NCT03599284
Drug: Vicagrel 5mg
Normalized name: Vicagrel
DrugBank: Vicagrel (DB16349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days
Study: NCT03599284
Drug: Vicagrel 6mg
Normalized name: Vicagrel
DrugBank: Vicagrel (DB16349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days